SCHEMBL2083556

SCHEMBL2083556

CC1(c2ccc([N+](=O)[O-])cc2)OCCCO1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.44
ACHE P22303 1/20 0.44
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 4/20 0.41
LMNA P02545 4/20 0.41
MAPT P10636 3/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
RECQL P46063 1/20 0.40
HTR1E P28566 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
S1PR3 Q99500 1/20 0.40
NOS1 P29475 2/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2082451 0.93 HSD17B10 (0.47) HSD17B10ACHEMAPK1ALDH1A1LMNA
SCHEMBL10978752 0.82 MAPK1 (0.67) MAPK1ALDH1A1LMNAMAPTPOLB
SCHEMBL10453479 0.77 MAPT (0.39) HSD17B10ACHEMAPK1ALDH1A1LMNA
SCHEMBL17596778 0.76 HSD17B10 (0.48) HSD17B10ACHEMAPK1ALDH1A1LMNA
SCHEMBL10864966 0.76 ESPL1 (0.42) HSD17B10ACHEMAPK1ALDH1A1LMNA
SCHEMBL27805323 0.76 HSD17B10 (0.48) HSD17B10ACHEMAPK1ALDH1A1LMNA
SCHEMBL2084708 0.75 SLC6A2 (0.40) HSD17B10ACHEMAPK1ALDH1A1LMNA
SCHEMBL9017957 0.75 NPC1 (0.41) MAPK1ALDH1A1LMNAMAPTHTR1E
SCHEMBL29054794 0.73 MAPT (0.39) HSD17B10ACHEMAPK1ALDH1A1LMNA
SCHEMBL6650386 0.73 TAAR1 (0.40) HSD17B10MAPK1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112927938-B Electrolyte for aluminum electrolytic capacitor, and electronic device 深圳市智胜新电子技术有限公司 2023-02-03 CN claimed
CN-112927938-A Electrolyte for aluminum electrolytic capacitor, and electronic device 深圳市智胜新电子技术有限公司 2021-06-08 CN claimed
CN-109390156-B One kind disappears hydrogen agent and preparation method thereof, aluminum electrolytic capacitor electrolyte 惠州市宙邦化工有限公司 2019-11-15 CN claimed
CN-109390156-A One kind disappears hydrogen agent and preparation method thereof, aluminum electrolytic capacitor electrolyte 惠州市宙邦化工有限公司 2019-02-26 CN claimed
EP-1611120-A4 NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES CORTICAL PTY LTD (AU) 2008-04-23 EP claimed
US-20070010563-A1 Novel methods for the treatment of inflammatory diseases CORTICAL PTY LTD (AU) 2007-01-11 US claimed
EP-1611120-A1 NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES Cortical Pty Ltd (AU) 2006-01-04 EP claimed
WO-2004089927-A1 NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES CORTICAL PTY LTD (AU) 2004-10-21 WO claimed
CN-112927938-B Electrolyte for aluminum electrolytic capacitor, and electronic device 深圳市智胜新电子技术有限公司 2023-02-03 CN disclosed
CN-112927938-A Electrolyte for aluminum electrolytic capacitor, and electronic device 深圳市智胜新电子技术有限公司 2021-06-08 CN disclosed
CN-109390156-B One kind disappears hydrogen agent and preparation method thereof, aluminum electrolytic capacitor electrolyte 惠州市宙邦化工有限公司 2019-11-15 CN disclosed
CN-109390156-A One kind disappears hydrogen agent and preparation method thereof, aluminum electrolytic capacitor electrolyte 惠州市宙邦化工有限公司 2019-02-26 CN disclosed
US-7863313-B2 Methods for the treatment of inflammatory diseases CORTICAL PTY LTD (AU) 2011-01-04 US disclosed
US-7863313-B2 Methods for the treatment of inflammatory diseases CORTICAL PTY LTD (AU) 2011-01-04 US disclosed
EP-1611120-A4 NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES CORTICAL PTY LTD (AU) 2008-04-23 EP disclosed
US-20070010563-A1 Novel methods for the treatment of inflammatory diseases CORTICAL PTY LTD (AU) 2007-01-11 US disclosed
US-20070010563-A1 Novel methods for the treatment of inflammatory diseases CORTICAL PTY LTD (AU) 2007-01-11 US disclosed
US-20070010563-A1 Novel methods for the treatment of inflammatory diseases CORTICAL PTY LTD (AU) 2007-01-11 US disclosed
EP-1611120-A1 NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES Cortical Pty Ltd (AU) 2006-01-04 EP disclosed
WO-2004089927-A1 NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES CORTICAL PTY LTD (AU) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010563-A1 Novel methods for the treatment of inflammatory diseases MIF, CCL2, CCL11 HSD17B10 1623/4885ACHE 3239/4885MAPK1 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.